First-in-Human trial launches for Off-the-Shelf CAR-NK therapy against tough cancers
NCT ID NCT07366658
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new cell therapy called NEUK203-13 for people with advanced small cell lung cancer or other neuroendocrine tumors that have not responded to standard treatments. The therapy uses immune cells (NK cells) made from stem cells and engineered to target a protein called DLL3 on cancer cells. The main goal is to check safety and tolerability, while also looking for early signs that the therapy might control tumor growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NEUK203-13 injection (a CAR-NK cell therapy made from stem cells, targeting DLL3 on cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced small cell lung cancer or other neuroendocrine tumors that have stopped responding to standard therapy.
What could go wrong
This is a very early Phase 1 trial with only 9 participants, so the main goal is safety, not proof of effectiveness. The therapy may not shrink tumors, and there are risks like cytokine release syndrome (CRS) and nerve-related side effects (ICANS).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital of CICAMS
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact